FDA moves a step closer to executive prosecutions

The FDA initiated 600 criminal prosecutions against companies in 1939 and it seems to be longing for the good old days. Its Office of Criminal Investigations, recently focused on fraud cases, appears ready for a shift to manufacturing as drug and device recalls grab headlines. CNN Money says the regulator has grown weary of protracted warning letter correspondence. It's studying the dusty Park Doctrine, under which it can prosecute corporate executives for manufacturing as well as other lapses. "It's going to happen. Do what you can and do the right thing before we find out about it," the story quotes an FDA official. Article

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.